Navigation Links
Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival,Benefits as Mitigator Against Radiation-Induced Damage in Study

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in our filings with the Securities and Exchange Commission.

     Contacts:

     The Global Consulting Group

     Rachel Levine

     T: (646) 284-9439

     E:
rlevine@hfgcg.com

Cleveland BioLabs, Inc.

CONTACT: Rachel Levine of The Global Consulting Group, +1-646-284-9439,, for Cleveland BioLabs, Inc. rlevine@hfgcg.com

Web site: http://www.cbiolabs.com/

Ticker Symbol: (NASDAQ-NMS:CBLI)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Cholesterol Drug Fails to Slow Progression of Coronary Disease, Cleveland Clinic Study Reports
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
7. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
8. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
(Date:11/25/2008)...Nov. 25 Proteolix, Inc., a,leader...utics that target,protein degradation pathways in...that data from two ongoing Phase 2 clinical trials...nted at the upcoming 50th Annual Meeting of the,A...is the first in a new class,of specific proteasom...
(Date:11/25/2008)...ical Trial to Assess Survival of Patients Receivin...ectable Hepatocellular Carcinoma , , BELLEV...Oncology, Inc. (LSO) today announced the completio... of Light Infusion Therapy(TM) (Litx(TM)) as a tre...HCC), also known as hepatoma or primary liver canc...
(Date:11/24/2008)...Newswire/ -- Domino,s Pizza (NYSE: DPZ ), the,r...ng up to raise dough for,the kids of St. Jude Chi...,Thanks and Giving campaign. Domino,s customers wi...nt of purchase to benefit the children of St. Jude...one or when ordering online at, www.dominos.com ....
(Date:11/24/2008)...ion leadership and long-term commitment to hepatit...PRNewswire-FirstCall/ -- Schering-Plough Corporati... on boceprevir, its lead investigational oral hepa...development. The company believes boceprevir has ...lass protease inhibitor for treating chronic hepat...
Breaking Medicine Technology:Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Gene Mutation Puts Some Kids at Risk for Tobacco Addiction 24151 1Gene Mutation Puts Some Kids at Risk for Tobacco Addiction 24151 2U S Health Care Still Ill Survey Finds 24149 1U S Health Care Still Ill Survey Finds 24149 2U S Health Care Still Ill Survey Finds 24149 3Aethons Train Themed Delivery Robot Available To Childrens Hospitals Nationwide 24147 1Aethons Train Themed Delivery Robot Available To Childrens Hospitals Nationwide 24147 2WeissComm Partners Ranks Among Top 5 Best U S Midsize PR Agencies to Work For 24145 1WeissComm Partners Ranks Among Top 5 Best U S Midsize PR Agencies to Work For 24145 2
(Date:12/2/2008)...f., Dec. 2 Internationally recogni...an invited speaker for this,year,s annual meeting... (Photo: http://www.newscom.com/cgi-bin/prnh...y is minimally invasive (or ,Goldilocks,) anesthes...d ,PK 101, minimally invasive,anesthesia for mini...
(Date:12/2/2008)...ica, Dec. 2 The Healthcare group a...ost.com ) is pleased to announce that,it will be ...dustry in,sub-Saharan Africa on Friday 12 Decembe...www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , ...althcare services is a,relatively novel concept i...
(Date:12/2/2008)... For many families, the problem with the holi...vides insight into how caregivers of aging parents...der care experience. , Sa...amilies the stress of the holiday season is family...er care expert Esther Koch , founder of Encore M...
(Date:12/2/2008)... Orion Health announces that the SouthEast Al..., Alaska, has selected the Rhapsody™ Integra...h record, radiology, pharmacy, laboratory and busi... plans to extend connectivity to statewide systems... registry) and AKAIMS (an MIS and clinical documen...
Breaking Medicine News(10 mins):Health News:The Future of Financing Health Services in Africa 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3
...ished in The Lancet on adolescent health, the curr...ompared to their parents.// The infections of the ...en way to venereal diseases, drinking, smoking, ob...er lining to this issue is that these conditions c...
...eart disease medicine of Sanofi-Aventis will be ma... the pharma company on Tuesday.// As per the offe...approved plans to buy or make imitated version of ...drug firm states that indigenous making of the hea...
...e the latest trend which is making waves in the he...arn and develop their skills to make sure the eval... of patients. More than 170 physician performanc...a, heart failure and emergency care through the Ph...
... aerated drink manufacturers Pepsico and Coca Cola...// The Ganguly report had deduced that pesticide r...Pepsico and Coca cola should be furnished within s...a civil society group had filed a public interest ...
Other Medicine News:
...ased, 2-8-channel system for measuring bioelectric...optic nerve. The basic set comprises: computer dev...ioelectrical amplifier, electrodes and checkerboar...o install. The recorded curves are displayed on a ...
A sophisticated research tool that allows to see the fundus picture of the area which is being stimulated. Besides it also includes the refractive pupil camera enabling the examiner to switch between
5 mm
Cannula and irrigation extension. Overall Length 150 mm (6.25"). Light Curve.
Medicine Products: